Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02916771 · ClinicalTrials.gov registry record · Phase 2
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
A Phase 2 study of Smoldering Multiple Myeloma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT02916771: Completed Phase 2 study of Smoldering Multiple Myeloma, sponsored by Dana-Farber Cancer Institute.
NCT02916771 is a Phase 2 study of Smoldering Multiple Myeloma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 61 participants, below the 797-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02916771, a Phase 2 study of Smoldering Multiple Myeloma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.
Primary Outcome
The proportion of patients who achieve progression free at 2 years will be compared to the rate published for the high risk SMM. By the Mayo Clinic model for risk factors, the median time to progression for patients with high risk SMM was only 1.9 years. Therefore, we assume that, a 2-years progression-free rate of 50% will not be considered promising and a true progression free rate of 75% or higher will be considered promising.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Ixazomib
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2016-10 |
| Est. Completion | 2025-01-08 |
| Phase | Phase 2 |
What the finished NCT02916771 record still lists
NCT02916771 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 797-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02916771 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02916771 about?
NCT02916771 is a clinical study titled "Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma". This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.
What is the current status of trial NCT02916771?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2016-10. Estimated completion is 2025-01-08.
What conditions does trial NCT02916771 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma.
What interventions are being tested in trial NCT02916771?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT02916771?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02916771 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02916771's enrollment target sits among peer trials
61 13th of 20 higher than 8 of 20 other Smoldering Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoldering Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
ACTIVE NOT RECRUITING · Phase 2
-
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia